{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T23:46:58Z","timestamp":1788997618790,"version":"build-2803163510"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,19]]},"DOI":"10.7759\/cureus.101867","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T20:58:24Z","timestamp":1768856304000},"source":"Crossref","is-referenced-by-count":3,"title":["Guideline-Directed Medical Therapy for Diabetic Kidney Disease: Advances in Primary and Secondary Prevention"],"prefix":"10.7759","author":[{"given":"Sidhant","family":"Verma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susant","family":"Katwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harshika Reddy","family":"Akula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfiya","family":"Inamdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah S","family":"Kundukulam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariyam","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad Bin Abdul Qayyum","family":"Satti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shweta","family":"Menon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manju","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2015.173","article-title":"Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease","volume":"12","author":"Thomas MC","year":"2016","unstructured":"Thomas MC, Cooper ME, Zimmet P. Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nat Rev Nephrol. 2016, 12:73-81. 10.1038\/nrneph.2015.173","journal-title":"Nat Rev Nephrol"},{"key":"ref2","article-title":"IDF Diabetes Atlas, 10th Edition","author":"Magliano DJ","year":"2021","unstructured":"Magliano DJ, Boyko EJ, Balkau B, et al.. IDF Diabetes Atlas, 10th Edition. Boyko EJ, Magliano DJ, Karuranga S, Piemonte L, Riley P, Saeedi P, Sun H (ed): International Diabetes Federation, Brussels, Belgium; 2021."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris GL","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, et al.. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020, 383:2219-29. 10.1056\/NEJMoa2025845","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2016.10.36","article-title":"Cardio-renal protection with empagliflozin","volume":"4","author":"MacIsaac RJ","year":"2016","unstructured":"MacIsaac RJ, Jerums G, Ekinci EI. Cardio-renal protection with empagliflozin. Ann Transl Med. 2016, 4:409. 10.21037\/atm.2016.10.36","journal-title":"Ann Transl Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2010010010","article-title":"Pathologic classification of diabetic nephropathy","volume":"21","author":"Tervaert TW","year":"2010","unstructured":"Tervaert TW, Mooyaart AL, Amann K, et al.. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol. 2010, 21:556-63. 10.1681\/ASN.2010010010","journal-title":"J Am Soc Nephrol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119163","article-title":"Podocyte loss and progressive glomerular injury in type II diabetes","volume":"99","author":"Pagtalunan ME","year":"1997","unstructured":"Pagtalunan ME, Miller PL, Jumping-Eagle S, et al.. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest. 1997, 99:342-8. 10.1172\/JCI119163","journal-title":"J Clin Invest"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2337\/diab.43.11.1358","article-title":"Glomerular structure in nonproteinuric IDDM patients with various levels of albuminuria","volume":"43","author":"Fioretto P","year":"1994","unstructured":"Fioretto P, Steffes MW, Mauer M. Glomerular structure in nonproteinuric IDDM patients with various levels of albuminuria. Diabetes. 1994, 43:1358-64. 10.2337\/diab.43.11.1358","journal-title":"Diabetes"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2007091048","article-title":"The role of inflammatory cytokines in diabetic nephropathy","volume":"19","author":"Navarro-Gonz\u00e1lez JF","year":"2008","unstructured":"Navarro-Gonz\u00e1lez JF, Mora-Fern\u00e1ndez C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol. 2008, 19:433-42. 10.1681\/ASN.2007091048","journal-title":"J Am Soc Nephrol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2147\/IJNRD.S40172","article-title":"Diabetic nephropathy - complications and treatment","volume":"7","author":"Lim AK","year":"2014","unstructured":"Lim AK. Diabetic nephropathy - complications and treatment. Int J Nephrol Renovasc Dis. 2014, 7:361-81. 10.2147\/IJNRD.S40172","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1369\/0022155412465073","article-title":"Diabetic nephropathy and extracellular matrix","volume":"60","author":"Kolset SO","year":"2012","unstructured":"Kolset SO, Reinholt FP, Jenssen T. Diabetic nephropathy and extracellular matrix. J Histochem Cytochem. 2012, 60:976-86. 10.1369\/0022155412465073","journal-title":"J Histochem Cytochem"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2003.00712.x","article-title":"Development and progression of nephropathy in type 2 diabetes: the United Kingdom prospective diabetes study (UKPDS 64)","volume":"63","author":"Adler AI","year":"2003","unstructured":"Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and progression of nephropathy in type 2 diabetes: the United Kingdom prospective diabetes study (UKPDS 64). Kidney Int. 2003, 63:225-32. 10.1046\/j.1523-1755.2003.00712.x","journal-title":"Kidney Int"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.1.164","article-title":"Diabetic nephropathy: diagnosis, prevention, and treatment","volume":"28","author":"Gross JL","year":"2005","unstructured":"Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005, 28:164-76. 10.2337\/diacare.28.1.164","journal-title":"Diabetes Care"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0299605","article-title":"Association between dyslipidemia and the risk of incident chronic kidney disease affected by genetic susceptibility: polygenic risk score analysis","volume":"19","author":"Weon B","year":"2024","unstructured":"Weon B, Jang Y, Jo J, et al.. Association between dyslipidemia and the risk of incident chronic kidney disease affected by genetic susceptibility: polygenic risk score analysis. PLoS One. 2024, 19:e0299605. 10.1371\/journal.pone.0299605","journal-title":"PLoS One"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2337\/db08-1514","article-title":"Genome-wide association scan for diabetic nephropathy susceptibility genes in type 1 diabetes","volume":"58","author":"Pezzolesi MG","year":"2009","unstructured":"Pezzolesi MG, Poznik GD, Mychaleckyj JC, et al.. Genome-wide association scan for diabetic nephropathy susceptibility genes in type 1 diabetes. Diabetes. 2009, 58:1403-10. 10.2337\/db08-1514","journal-title":"Diabetes"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-2042","article-title":"Diabetic neuropathy: a position statement by the American Diabetes Association","volume":"40","author":"Pop-Busui R","year":"2017","unstructured":"Pop-Busui R, Boulton AJ, Feldman EL, et al.. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care. 2017, 40:136-54. 10.2337\/dc16-2042","journal-title":"Diabetes Care"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00519-5","article-title":"Chronic kidney disease","volume":"398","author":"Kalantar-Zadeh K","year":"2021","unstructured":"Kalantar-Zadeh K, Jafar TH, Nitsch D, Neuen BL, Perkovic V. Chronic kidney disease. Lancet. 2021, 398:786-802. 10.1016\/S0140-6736(21)00519-5","journal-title":"Lancet"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.10924","article-title":"Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014","volume":"316","author":"Afkarian M","year":"2016","unstructured":"Afkarian M, Zelnick LR, Hall YN, Heagerty PJ, Tuttle K, Weiss NS, de Boer IH. Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014. JAMA. 2016, 316:602-10. 10.1001\/jama.2016.10924","journal-title":"JAMA"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/s41387-024-00285-3","article-title":"Mediterranean diet as a strategy for preserving kidney function in patients with coronary heart disease with type 2 diabetes and obesity: a secondary analysis of CORDIOPREV randomized controlled trial","volume":"14","author":"Podadera-Herreros A","year":"2024","unstructured":"Podadera-Herreros A, Arenas-de Larriva AP, Gutierrez-Mariscal FM, et al.. Mediterranean diet as a strategy for preserving kidney function in patients with coronary heart disease with type 2 diabetes and obesity: a secondary analysis of CORDIOPREV randomized controlled trial. Nutr Diabetes. 2024, 14:27. 10.1038\/s41387-024-00285-3","journal-title":"Nutr Diabetes"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2016.05.019","article-title":"DASH (dietary approaches to stop hypertension) diet and risk of subsequent kidney disease","volume":"68","author":"Rebholz CM","year":"2016","unstructured":"Rebholz CM, Crews DC, Grams ME, et al.. DASH (dietary approaches to stop hypertension) diet and risk of subsequent kidney disease. Am J Kidney Dis. 2016, 68:853-61. 10.1053\/j.ajkd.2016.05.019","journal-title":"Am J Kidney Dis"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014906.pub2","article-title":"Protein restriction for diabetic kidney disease","volume":"1","author":"Jiang S","year":"2023","unstructured":"Jiang S, Fang J, Li W. Protein restriction for diabetic kidney disease. Cochrane Database Syst Rev. 2023, 1:CD014906. 10.1002\/14651858.CD014906.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25073605","article-title":"Exercise in diabetic nephropathy: protective effects and molecular mechanism","volume":"25","author":"Li RY","year":"2024","unstructured":"Li RY, Guo L. Exercise in diabetic nephropathy: protective effects and molecular mechanism. Int J Mol Sci. 2024, 25:3605. 10.3390\/ijms25073605","journal-title":"Int J Mol Sci"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20203624","article-title":"Effects of physical activity on the progression of diabetic nephropathy: a meta-analysis","volume":"41","author":"Cai Z","year":"2021","unstructured":"Cai Z, Yang Y, Zhang J. Effects of physical activity on the progression of diabetic nephropathy: a meta-analysis. Biosci Rep. 2021, 41:BSR20203624. 10.1042\/BSR20203624","journal-title":"Biosci Rep"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-021-01429-w","article-title":"Association between exercise frequency with renal and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk","volume":"21","author":"B\u00f6hm M","year":"2022","unstructured":"B\u00f6hm M, Schumacher H, Werner C, et al.. Association between exercise frequency with renal and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk. Cardiovasc Diabetol. 2022, 21:12. 10.1186\/s12933-021-01429-w","journal-title":"Cardiovasc Diabetol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2003.50009","article-title":"Cigarette smoking and increased urine albumin excretion are interrelated predictors of nephropathy progression in type 2 diabetes","volume":"41","author":"Chuahirun T","year":"2003","unstructured":"Chuahirun T, Khanna A, Kimball K, Wesson DE. Cigarette smoking and increased urine albumin excretion are interrelated predictors of nephropathy progression in type 2 diabetes. Am J Kidney Dis. 2003, 41:13-21. 10.1053\/ajkd.2003.50009","journal-title":"Am J Kidney Dis"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfae268","article-title":"Smoking cessation and atherosclerotic cardiovascular events and mortality in chronic kidney disease","volume":"40","author":"Joo YS","year":"2025","unstructured":"Joo YS, Yun HR, Kim HW, et al.. Smoking cessation and atherosclerotic cardiovascular events and mortality in chronic kidney disease. Nephrol Dial Transplant. 2025, 40:1203-12. 10.1093\/ndt\/gfae268","journal-title":"Nephrol Dial Transplant"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-S011","article-title":"11. Chronic kidney disease and risk management: standards of care in diabetes\u20142023","volume":"46","author":"ElSayed NA","year":"2023","unstructured":"ElSayed NA, Aleppo G, Aroda VR, et al.. 11. Chronic kidney disease and risk management: standards of care in diabetes\u20142023. Diabetes Care. 2023, 46:S191-202. 10.2337\/dc23-S011","journal-title":"Diabetes Care"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39478.378241.BE","article-title":"Risk of microalbuminuria and progression to macroalbuminuria in a cohort with childhood onset type 1 diabetes: prospective observational study","volume":"336","author":"Amin R","year":"2008","unstructured":"Amin R, Widmer B, Prevost AT, et al.. Risk of microalbuminuria and progression to macroalbuminuria in a cohort with childhood onset type 1 diabetes: prospective observational study. BMJ. 2008, 336:697-701. 10.1136\/bmj.39478.378241.BE","journal-title":"BMJ"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2013.12.012","article-title":"Cost-effectiveness of primary screening for CKD: a systematic review","volume":"63","author":"Komenda P","year":"2014","unstructured":"Komenda P, Ferguson TW, Macdonald K, Rigatto C, Koolage C, Sood MM, Tangri N. Cost-effectiveness of primary screening for CKD: a systematic review. Am J Kidney Dis. 2014, 63:789-97. 10.1053\/j.ajkd.2013.12.012","journal-title":"Am J Kidney Dis"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Stevens PE","year":"2024","unstructured":"Stevens PE, Ahmed SB, Carrero JJ, et al.. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024, 105:S117-314. 10.1016\/j.kint.2023.10.018","journal-title":"Kidney Int"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfad082","article-title":"EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors","volume":"16","author":"Fern\u00e1ndez-Fernandez B","year":"2023","unstructured":"Fern\u00e1ndez-Fernandez B, Sarafidis P, Soler MJ, Ortiz A. EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors. Clin Kidney J. 2023, 16:1187-98. 10.1093\/ckj\/sfad082","journal-title":"Clin Kidney J"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.7326\/M23-2788","article-title":"Newer pharmacologic treatments in adults with type 2 diabetes: a clinical guideline from the American College of Physicians","volume":"177","author":"Qaseem A","year":"2024","unstructured":"Qaseem A, Obley AJ, Shamliyan T, et al.. Newer pharmacologic treatments in adults with type 2 diabetes: a clinical guideline from the American College of Physicians. Ann Intern Med. 2024, 177:658-66. 10.7326\/M23-2788","journal-title":"Ann Intern Med"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.240922","article-title":"Sodium-glucose cotransporter 2 (SGLT2) inhibitors and risk of chronic kidney disease-mineral and bone disorders in patients with type 2 diabetes mellitus and stage 1-3 chronic kidney disease","volume":"197","author":"Tsai DH","year":"2025","unstructured":"Tsai DH, Chuang AT, Liu KH, Shao SC, Lai EC. Sodium-glucose cotransporter 2 (SGLT2) inhibitors and risk of chronic kidney disease-mineral and bone disorders in patients with type 2 diabetes mellitus and stage 1-3 chronic kidney disease. CMAJ. 2025, 197:E178-89. 10.1503\/cmaj.240922","journal-title":"CMAJ"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.163.13.1555","article-title":"Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study","volume":"163","author":"Bakris GL","year":"2003","unstructured":"Bakris GL, Weir MR, Shanifar S, Zhang Z, Douglas J, van Dijk DJ, Brenner BM. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med. 2003, 163:1555-65. 10.1001\/archinte.163.13.1555","journal-title":"Arch Intern Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis EJ","year":"2001","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR, et al.. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001, 345:851-60. 10.1056\/NEJMoa011303","journal-title":"N Engl J Med"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-S011","article-title":"11. Chronic kidney disease and risk management: standards of care in diabetes\u20142024","volume":"47","author":"ElSayed NA","year":"2024","unstructured":"ElSayed NA, Aleppo G, Bannuru RR, et al.. 11. Chronic kidney disease and risk management: standards of care in diabetes\u20142024. Diabetes Care. 2024, 47:S219-30. 10.2337\/dc24-S011","journal-title":"Diabetes Care"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30104-9","article-title":"Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial","volume":"6","author":"Tuttle KR","year":"2018","unstructured":"Tuttle KR, Lakshmanan MC, Rayner B, Busch RS, Zimmermann AG, Woodward DB, Botros FT. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 2018, 6:605-17. 10.1016\/S2213-8587(18)30104-9","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62305-7","article-title":"Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial","volume":"377","author":"Zinman B","year":"2011","unstructured":"Zinman B, Fulcher G, Rao PV, et al.. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. Lancet. 2011, 377:924-31. 10.1016\/S0140-6736(10)62305-7","journal-title":"Lancet"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1203858","article-title":"Basal insulin and cardiovascular and other outcomes in dysglycemia","volume":"367","author":"Gerstein HC","year":"2012","unstructured":"Gerstein HC, Bosch J, Dagenais GR, et al.. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012, 367:319-28. 10.1056\/NEJMoa1203858","journal-title":"N Engl J Med"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso SP","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al.. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016, 375:311-22. 10.1056\/NEJMoa1603827","journal-title":"N Engl J Med"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso SP","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al.. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016, 375:1834-44. 10.1056\/NEJMoa1607141","journal-title":"N Engl J Med"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1161\/HYP.0000000000000066","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"71","author":"Whelton PK","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, et al.. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines. Hypertension. 2018, 71:1269-324. 10.1161\/HYP.0000000000000066","journal-title":"Hypertension"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001286","article-title":"Effects of intensive blood-pressure control in type 2 diabetes mellitus","volume":"362","author":"Cushman WC","year":"2010","unstructured":"Cushman WC, Evans GW, Byington RP, et al.. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010, 362:1575-85. 10.1056\/NEJMoa1001286","journal-title":"N Engl J Med"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.11.003","article-title":"KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease","volume":"99","author":"Cheung AK","year":"2021","unstructured":"Cheung AK, Chang TI, Cushman WC, et al.. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2021, 99:S1-87. 10.1016\/j.kint.2020.11.003","journal-title":"Kidney Int"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner BM","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeeuw D, et al.. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001, 345:861-9. 10.1056\/NEJMoa011161","journal-title":"N Engl J Med"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt B","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, et al.. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021, 385:2252-63. 10.1056\/NEJMoa2110956","journal-title":"N Engl J Med"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.028268","article-title":"Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease","volume":"137","author":"Wanner C","year":"2018","unstructured":"Wanner C, Lachin JM, Inzucchi SE, et al.. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation. 2018, 137:119-29. 10.1161\/CIRCULATIONAHA.117.028268","journal-title":"Circulation"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink HJ","year":"2020","unstructured":"Heerspink HJ, Stef\u00e1nsson BV, Correa-Rotter R, et al.. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020, 383:1436-46. 10.1056\/NEJMoa2024816","journal-title":"N Engl J Med"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington WG","year":"2023","unstructured":"Herrington WG, Staplin N, Wanner C, et al.. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023, 388:117-27. 10.1056\/NEJMoa2204233","journal-title":"N Engl J Med"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1213473","article-title":"Role and mechanisms of SGLT-2 inhibitors in the treatment of diabetic kidney disease","volume":"14","author":"Dai ZC","year":"2023","unstructured":"Dai ZC, Chen JX, Zou R, Liang XB, Tang JX, Yao CW. Role and mechanisms of SGLT-2 inhibitors in the treatment of diabetic kidney disease. Front Immunol. 2023, 14:1213473. 10.3389\/fimmu.2023.1213473","journal-title":"Front Immunol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic V","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al.. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019, 380:2295-306. 10.1056\/NEJMoa1811744","journal-title":"N Engl J Med"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.4103\/jod.jod_98_23","article-title":"Assessment of effects of combination of SGLT2 inhibitors and renin-angiotensin-aldosterone system blockers on the renal functions of patients of diabetic kidney disease (SGRASS-DKD study)","volume":"15","author":"Halder S","year":"2024","unstructured":"Halder S, Bhattacharyya A, Mukherjee S, Konar B, Halder A. Assessment of effects of combination of SGLT2 inhibitors and renin-angiotensin-aldosterone system blockers on the renal functions of patients of diabetic kidney disease (SGRASS-DKD study). J Diabetol. 2024, 15:79-85. 10.4103\/jod.jod_98_23","journal-title":"J Diabetol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-021-01118-7","article-title":"Effect of mineralocorticoid receptor antagonism and ACE inhibition on angiotensin profiles in diabetic kidney disease: an exploratory study","volume":"12","author":"Kovarik JJ","year":"2021","unstructured":"Kovarik JJ, Kaltenecker CC, Domenig O, Antlanger M, Poglitsch M, Kopecky C, S\u00e4emann MD. Effect of mineralocorticoid receptor antagonism and ACE inhibition on angiotensin profiles in diabetic kidney disease: an exploratory study. Diabetes Ther. 2021, 12:2485-98. 10.1007\/s13300-021-01118-7","journal-title":"Diabetes Ther"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfac198","article-title":"Design of the combination effect of finerenone and empagliflozin in participants with chronic kidney disease and type 2 diabetes using a UACR endpoint study (CONFIDENCE)","volume":"38","author":"Green JB","year":"2023","unstructured":"Green JB, Mottl AK, Bakris G, et al.. Design of the combination effect of finerenone and empagliflozin in participants with chronic kidney disease and type 2 diabetes using a UACR endpoint study (CONFIDENCE). Nephrol Dial Transplant. 2023, 38:894-903. 10.1093\/ndt\/gfac198","journal-title":"Nephrol Dial Transplant"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein HC","year":"2021","unstructured":"Gerstein HC, Sattar N, Rosenstock J, et al.. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med. 2021, 385:896-907. 10.1056\/NEJMoa2108269","journal-title":"N Engl J Med"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-0382","article-title":"Dapagliflozin and prevention of kidney disease among patients with type 2 diabetes: post hoc analyses from the DECLARE-TIMI 58 trial","volume":"45","author":"Mosenzon O","year":"2022","unstructured":"Mosenzon O, Raz I, Wiviott SD, et al.. Dapagliflozin and prevention of kidney disease among patients with type 2 diabetes: post hoc analyses from the DECLARE-TIMI 58 trial. Diabetes Care. 2022, 45:2350-9. 10.2337\/dc22-0382","journal-title":"Diabetes Care"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11092653","article-title":"The effects of dipeptidyl peptidase 4 inhibitors on renal function in patients with type 2 diabetes mellitus","volume":"11","author":"Hsu WC","year":"2022","unstructured":"Hsu WC, Lin CS, Chen JF, Chang CM. The effects of dipeptidyl peptidase 4 inhibitors on renal function in patients with type 2 diabetes mellitus. J Clin Med. 2022, 11:2653. 10.3390\/jcm11092653","journal-title":"J Clin Med"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1111\/nep.14130","article-title":"Endothelin receptor antagonists in kidney protection for diabetic kidney disease and beyond?","volume":"28","author":"Chung EY","year":"2023","unstructured":"Chung EY, Badve SV, Heerspink HJ, Wong MG. Endothelin receptor antagonists in kidney protection for diabetic kidney disease and beyond?. Nephrology (Carlton). 2023, 28:97-108. 10.1111\/nep.14130","journal-title":"Nephrology (Carlton)"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.3390\/cimb46120816","article-title":"Open-label clinical trial on the impact of autologous dendritic cell therapy on albuminuria and inflammatory biomarkers (interleukin-6, interleukin-10, tumor necrosis factor \u03b1) in diabetic kidney disease (DKD)","volume":"46","author":"Jonny","year":"2024","unstructured":"Jonny, Sitepu EC, Hernowo BA, Chiuman L, Lister IN, Putranto TA. Open-label clinical trial on the impact of autologous dendritic cell therapy on albuminuria and inflammatory biomarkers (interleukin-6, interleukin-10, tumor necrosis factor \u03b1) in diabetic kidney disease (DKD). Curr Issues Mol Biol. 2024, 46:13662-74. 10.3390\/cimb46120816","journal-title":"Curr Issues Mol Biol"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfx377","article-title":"JAK1\/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a phase 2 randomized controlled clinical trial","volume":"33","author":"Tuttle KR","year":"2018","unstructured":"Tuttle KR, Brosius FC 3rd, Adler SG, et al.. JAK1\/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a phase 2 randomized controlled clinical trial. Nephrol Dial Transplant. 2018, 33:1950-9. 10.1093\/ndt\/gfx377","journal-title":"Nephrol Dial Transplant"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2020.03.030","article-title":"Randomized clinical trial on the effect of bardoxolone methyl on GFR in diabetic kidney disease patients (TSUBAKI study)","volume":"5","author":"Nangaku M","year":"2020","unstructured":"Nangaku M, Kanda H, Takama H, Ichikawa T, Hase H, Akizawa T. Randomized clinical trial on the effect of bardoxolone methyl on GFR in diabetic kidney disease patients (TSUBAKI study). Kidney Int Rep. 2020, 5:879-90. 10.1016\/j.ekir.2020.03.030","journal-title":"Kidney Int Rep"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S010","article-title":"10. Cardiovascular disease and risk management: standards of care in diabetes\u20142025","volume":"48","author":"ElSayed NA","year":"2025","unstructured":"ElSayed NA, McCoy RG, Aleppo G, et al.. 10. Cardiovascular disease and risk management: standards of care in diabetes\u20142025. Diabetes Care. 2025, 48:S207-38. 10.2337\/dc25-S010","journal-title":"Diabetes Care"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-S010","article-title":"10. Cardiovascular disease and risk management: standards of care in diabetes\u20142024","volume":"47","author":"ElSayed NA","year":"2024","unstructured":"ElSayed NA, Aleppo G, Bannuru RR, et al.. 10. Cardiovascular disease and risk management: standards of care in diabetes\u20142024. Diabetes Care. 2024, 47:S179-218. 10.2337\/dc24-S010","journal-title":"Diabetes Care"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Cosentino F","year":"2020","unstructured":"Cosentino F, Grant PJ, Aboyans V, et al.. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J. 2020, 41:255-323. 10.1093\/eurheartj\/ehz486","journal-title":"Eur Heart J"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx N","year":"2023","unstructured":"Marx N, Federici M, Sch\u00fctt K, et al.. 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023, 44:4043-140. 10.1093\/eurheartj\/ehad192","journal-title":"Eur Heart J"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James PA","year":"2014","unstructured":"James PA, Oparil S, Carter BL, et al.. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014, 311:507-20. 10.1001\/jama.2013.284427","journal-title":"JAMA"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2022.06.008","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","author":"Rossing P","year":"2022","unstructured":"Rossing P, Caramori ML, Chan JC, et al.. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022, 102:S1-127. 10.1016\/j.kint.2022.06.008","journal-title":"Kidney Int"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-020-01731-x","article-title":"Barriers and enablers to detection and management of chronic kidney disease in primary healthcare: a systematic review","volume":"21","author":"Neale EP","year":"2020","unstructured":"Neale EP, Middleton J, Lambert K. Barriers and enablers to detection and management of chronic kidney disease in primary healthcare: a systematic review. BMC Nephrol. 2020, 21:83. 10.1186\/s12882-020-01731-x","journal-title":"BMC Nephrol"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2020.11.039","article-title":"Adherence to the Kidney Disease: Improving Global Outcomes CKD guideline in nephrology practice across countries","volume":"6","author":"Stengel B","year":"2021","unstructured":"Stengel B, Muenz D, Tu C, et al.. Adherence to the Kidney Disease: Improving Global Outcomes CKD guideline in nephrology practice across countries. Kidney Int Rep. 2021, 6:437-48. 10.1016\/j.ekir.2020.11.039","journal-title":"Kidney Int Rep"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2017.06.003","article-title":"Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus","volume":"43","author":"Reach G","year":"2017","unstructured":"Reach G, Pechtner V, Gentilella R, Corcos A, Ceriello A. Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus. Diabetes Metab. 2017, 43:501-11. 10.1016\/j.diabet.2017.06.003","journal-title":"Diabetes Metab"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1177\/2042018819844694","article-title":"Therapeutic inertia in type 2 diabetes: prevalence, causes, consequences and methods to overcome inertia","volume":"10","author":"Khunti S","year":"2019","unstructured":"Khunti S, Khunti K, Seidu S. Therapeutic inertia in type 2 diabetes: prevalence, causes, consequences and methods to overcome inertia. Ther Adv Endocrinol Metab. 2019, 10:2042018819844694. 10.1177\/2042018819844694","journal-title":"Ther Adv Endocrinol Metab"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2012.03605.x","article-title":"Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study","volume":"29","author":"Peyrot M","year":"2012","unstructured":"Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med. 2012, 29:682-9. 10.1111\/j.1464-5491.2012.03605.x","journal-title":"Diabet Med"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfz054","article-title":"Non-steroidal anti-inflammatory drugs in chronic kidney disease: a systematic review of prescription practices and use in primary care","volume":"13","author":"Lefebvre C","year":"2020","unstructured":"Lefebvre C, Hindi\u00e9 J, Zappitelli M, Platt RW, Filion KB. Non-steroidal anti-inflammatory drugs in chronic kidney disease: a systematic review of prescription practices and use in primary care. Clin Kidney J. 2020, 13:63-71. 10.1093\/ckj\/sfz054","journal-title":"Clin Kidney J"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2013.06.012","article-title":"Breaking down patient and physician barriers to optimize glycemic control in type 2 diabetes","volume":"126","author":"Ross SA","year":"2013","unstructured":"Ross SA. Breaking down patient and physician barriers to optimize glycemic control in type 2 diabetes. Am J Med. 2013, 126:S38-48. 10.1016\/j.amjmed.2013.06.012","journal-title":"Am J Med"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2021.4205","article-title":"Coverage, formulary restrictions, and affordability of sodium-glucose cotransporter 2 inhibitors by US insurance plan types","volume":"2","author":"Tummalapalli SL","year":"2021","unstructured":"Tummalapalli SL, Montealegre JL, Warnock N, Green M, Ibrahim SA, Estrella MM. Coverage, formulary restrictions, and affordability of sodium-glucose cotransporter 2 inhibitors by US insurance plan types. JAMA Health Forum. 2021, 2:e214205. 10.1001\/jamahealthforum.2021.4205","journal-title":"JAMA Health Forum"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1159\/000502602","article-title":"An integrated kidney care eConsult practice model: results from the iKinect project","volume":"50","author":"Ong SW","year":"2019","unstructured":"Ong SW, Kaushal A, Pariser P, Chan CT. An integrated kidney care eConsult practice model: results from the iKinect project. Am J Nephrol. 2019, 50:262-71. 10.1159\/000502602","journal-title":"Am J Nephrol"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1177\/193229681300700302","article-title":"Telemedicine diabetes consultations are cost-effective, and effects on essential diabetes treatment parameters are similar to conventional treatment: 7-year results from the Svendborg telemedicine diabetes project","volume":"7","author":"Levin K","year":"2013","unstructured":"Levin K, Madsen JR, Petersen I, Wanscher CE, Hangaard J. Telemedicine diabetes consultations are cost-effective, and effects on essential diabetes treatment parameters are similar to conventional treatment: 7-year results from the Svendborg telemedicine diabetes project. J Diabetes Sci Technol. 2013, 7:587-95. 10.1177\/193229681300700302","journal-title":"J Diabetes Sci Technol"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13417","article-title":"New clinical trial designs for establishing drug efficacy and safety in a precision medicine era","volume":"20","author":"Heerspink HJ","year":"2018","unstructured":"Heerspink HJ, List J, Perkovic V. New clinical trial designs for establishing drug efficacy and safety in a precision medicine era. Diabetes Obes Metab. 2018, 20:14-8. 10.1111\/dom.13417","journal-title":"Diabetes Obes Metab"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00360119","article-title":"Development and validation of a pragmatic electronic phenotype for CKD","volume":"14","author":"Norton JM","year":"2019","unstructured":"Norton JM, Ali K, Jurkovitz CT, et al.. Development and validation of a pragmatic electronic phenotype for CKD. Clin J Am Soc Nephrol. 2019, 14:1306-14. 10.2215\/CJN.00360119","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.10.033","article-title":"GLP-1 receptor agonist versus DPP-4 inhibitor and kidney and cardiovascular outcomes in clinical practice in type-2 diabetes","volume":"101","author":"Xu Y","year":"2022","unstructured":"Xu Y, Fu EL, Clase CM, Mazhar F, Jardine MJ, Carrero JJ. GLP-1 receptor agonist versus DPP-4 inhibitor and kidney and cardiovascular outcomes in clinical practice in type-2 diabetes. Kidney Int. 2022, 101:360-8. 10.1016\/j.kint.2021.10.033","journal-title":"Kidney Int"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2024.11.013","article-title":"Kidney and cardiovascular outcomes among patients with CKD receiving GLP-1 receptor agonists: a systematic review and meta-analysis of randomized trials","volume":"85","author":"Chen JY","year":"2025","unstructured":"Chen JY, Hsu TW, Liu JH, Pan HC, Lai CF, Yang SY, Wu VC. Kidney and cardiovascular outcomes among patients with CKD receiving GLP-1 receptor agonists: a systematic review and meta-analysis of randomized trials. Am J Kidney Dis. 2025, 85:555-69.e1. 10.1053\/j.ajkd.2024.11.013","journal-title":"Am J Kidney Dis"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.64038","article-title":"Assessing the renal outcomes of semaglutide in diabetic kidney disease: a systematic review","volume":"16","author":"Rehman SU","year":"2024","unstructured":"Rehman SU, Kolanu ND, Mushtaq MM, et al.. Assessing the renal outcomes of semaglutide in diabetic kidney disease: a systematic review. Cureus. 2024, 16:e64038. 10.7759\/cureus.64038","journal-title":"Cureus"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v11.i11.553","article-title":"Endothelin receptor antagonists for the treatment of diabetic nephropathy: a meta-analysis and systematic review","volume":"11","author":"Zhang L","year":"2020","unstructured":"Zhang L, Xue S, Hou J, Chen G, Xu ZG. Endothelin receptor antagonists for the treatment of diabetic nephropathy: a meta-analysis and systematic review. World J Diabetes. 2020, 11:553-66. 10.4239\/wjd.v11.i11.553","journal-title":"World J Diabetes"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14411","article-title":"Efficacy and safety of endothelin receptor antagonists in type 2 diabetic kidney disease: a systematic review and meta-analysis of randomized controlled trials","volume":"38","author":"Zhou Y","year":"2021","unstructured":"Zhou Y, Chi J, Huang Y, Dong B, Lv W, Wang YG. Efficacy and safety of endothelin receptor antagonists in type 2 diabetic kidney disease: a systematic review and meta-analysis of randomized controlled trials. Diabet Med. 2021, 38:e14411. 10.1111\/dme.14411","journal-title":"Diabet Med"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.45575","article-title":"Precision medicine approaches to diabetic kidney disease: personalized interventions on the horizon","volume":"15","author":"Nageeta F","year":"2023","unstructured":"Nageeta F, Waqar F, Allahi I, et al.. Precision medicine approaches to diabetic kidney disease: personalized interventions on the horizon. Cureus. 2023, 15:e45575. 10.7759\/cureus.45575","journal-title":"Cureus"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2011060628","article-title":"Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes","volume":"23","author":"Gohda T","year":"2012","unstructured":"Gohda T, Niewczas MA, Ficociello LH, et al.. Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes. J Am Soc Nephrol. 2012, 23:516-24. 10.1681\/ASN.2011060628","journal-title":"J Am Soc Nephrol"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15080973","article-title":"Emerging biomarkers and innovative therapeutic strategies in diabetic kidney disease: a pathway to precision medicine","volume":"15","author":"Shetty S","year":"2025","unstructured":"Shetty S, Suvarna R, Awasthi A, Bhojaraja MV, Pappachan JM. Emerging biomarkers and innovative therapeutic strategies in diabetic kidney disease: a pathway to precision medicine. Diagnostics (Basel). 2025, 15:973. 10.3390\/diagnostics15080973","journal-title":"Diagnostics (Basel)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/448220-guideline-directed-medical-therapy-for-diabetic-kidney-disease-advances-in-primary-and-secondary-prevention","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T20:58:25Z","timestamp":1768856305000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/448220-guideline-directed-medical-therapy-for-diabetic-kidney-disease-advances-in-primary-and-secondary-prevention"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":86,"URL":"https:\/\/doi.org\/10.7759\/cureus.101867","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,19]]}}}